
|Articles|March 20, 2020
MMS Offers $1M Award Toward COVID-19 Vaccine Development
Advertisement
MMS Holdings (MMS), a data-focused CRO, is offering a $1 million award toward the development of a vaccine for COVID-19. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or with other global health authorities. Organizations interested in applying for this award can submit a notification of interest at
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Workforce Compression in AI-Driven Clinical Trial Operations
2
Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First
3
From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting
4
Navigating the Adoption of Biomarker-Informed Trial Enrollment Beyond Oncology
5




